Innovative Drug Development in Asia: Challenges & Opportunities

**DRUG DEVELOPMENT TRACK**

*Offers both CME & CPE Credit*

UAN #JA4008220-0000-20-012-L04-P

ACPE – 3.5 CONTACT HOURS/KNOWLEDGE-BASED

**CO-CHAIRS:**

Haiyan Li, MD, Peking Univ Third Hosp, China
Gailing Li, PhD, Janssen Research & Development LLC

**TARGET AUDIENCE:**

This Workshop will be useful for clinical pharmacologists from academia and the pharmaceutical industry, public health researchers, physicians, pharmacists, pharmacometricians, pharmacokinetic/pharmacodynamic scientists and drug development scientists.

**GOALS & OBJECTIVES:**

Following the completion of this activity, the learner will be able to:

1. Be aware of drug development in Asia and potential opportunities for future collaborations;
2. Be aware of the growing role and responsibility of clinical pharmacology and pharmacometrics in transforming the pharmaceutical industry in Asia;
3. Apply clinical pharmacology & pharmacometrics knowledge and skills to facilitate the implementation of ICH E5 & E17;
4. Explore the opportunities for collaboration in education and training to facilitate the development of Asian capabilities and capacity in clinical pharmacology for a truly global effort in bringing innovative medicine to patients in need worldwide.

---

**Introduction**

Haiyan Li, MD, Peking Univ Third Hosp, China and Gailing Li, PhD, Janssen Research & Development LLC

**Innovative Drug Development in China: Challenges & Opportunities**

Haiyan Li, MD, Peking Univ Third Hosp, China

---

**Innovation Dismantled**

Nilima A. Kshirsagar, MBBS, MD, National Chair, Clinical Pharmacology, ICMR Gov’t of India

---

**Capability Building Through Collaboration**

Junko Sato, PhD, Director, Int’l Program, Pharmaceuticals & Medical Devices Agency

---

**Break**

---

**Early Phase Clinical Trials in Korea**

Howard Lee, MD, PhD, Clinical Pharmacology & Therapeutics, Seoul National Univ Hosp & Coll of Medicine

---

**Faculty Panel Discussion, Questions & Answers, Learner Feedback & Evaluation**